הסקירה באדיבות מדיקונטקסט:Last Updated: 2001-07-18 12:42:22 EDT (Reuters Health)
By Megan Rauscher
WESTPORT, CT (Reuters Health) – An association between two markers of systemic inflammation, C-reactive protein and interleukin 6, and the development of type 2 diabetes mellitus has emerged in a prospective, nested case-control study involving participants in the ongoing Women's Health Study, a primary prevention study launched in 1992.
Boston researchers led by Dr. Paul M. Ridker, of Brigham and Women's Hospital, report the finding today in the July 18th issue of The Journal of the American Medical Association, adding to the growing body of evidence that inflammation has a pathogenic role in diabetes.
Baseline levels of CRP and IL-6 were significantly higher (p < 0.001) in 188 women who developed diabetes than in 362 matched controls who did not develop the disease, according to the report. Women in the highest quartiles of CRP and IL-6 had relative risks of developing diabetes of 15.7 and 7.5, respectively, compared with women in the lowest quartiles.
On adjusted multivariate analysis, elevated CRP remained a "powerful independent" risk factor for diabetes. The impact of elevated IL-6 dropped to borderline statistical significance.
Dr. Ridker's team notes that these findings were "robust in sensitivity analyses limited to subjects with a baseline HbA1c of 6.0% of less and were consistently noted in both obese and nonobese individuals."
In comments to Reuters Health, Dr. Ridker said that "the data are very exciting because they suggest that there may be new ways to both detect and prevent diabetes. The data should also point us in several new directions in that they raise the possibility that anti-inflammatory strategies may hold promise for diabetes."